TY  - BOOK
AU  - Aptsiauri,Natalia
AU  - Garcia-Lora,Angel Miguel
AU  - Cabrera,Teresa
ED  - SpringerLink (Online service)
TI  - MHC Class I Antigens In Malignant Cells: Immune Escape And Response To Immunotherapy 
T2  - SpringerBriefs in Cancer Research
SN  - 9781461465430
AV  - RC261-271 
U1  - 614.5999 23
PY  - 2013///
CY  - New York, NY
PB  - Springer New York, Imprint: Springer
KW  - Medicine
KW  - Cancer research
KW  - Immunology
KW  - Molecular biology
KW  - Biomedicine
KW  - Cancer Research
KW  - Molecular Medicine
N1  - Overview of MHC Class I Antigens -- HLA Class I Expression In Human Cancer -- MHC Class I Expression In Experimental Mouse Models Of Cancer: Immunotherapy Of Tumors With Different MHC-I Expression Patterns -- Potential Therapeutic Approaches For Increasing Tumor Immunogenicity By Upregulation Of Tumor HLA Class I Expression -- Conclusion
N2  - Abnormal expression of MHC class I molecules in malignant cells is a frequent occurrence that ranges from total loss of all class I antigens to partial loss of MHC specific haplotypes or alleles. Different mechanisms are described to be responsible for these alterations, requiring different therapeutic approaches. A complete characterization of these molecular defects is important for improvement of the strategies for the selection and follow-up of patients undergoing T-cell based cancer immunotherapy.  Precise identification of the mechanism leading to MHC class I defects  will help to develop new personalized patient-tailored treatment protocols. There is significant new research on the prevalence of various patterns of MHC class I defects and the underlying molecular mechanisms in different types of cancer. In contrast, few data is available on the changes in MHC class I expression during the course of cancer immunotherapy, but the authors have recently made discoveries that show the progression or regression of a tumor lesion in cancer patients undergoing immunotherapy depends on the molecular mechanism responsible for the MHC class I alteration and not on the type of immunotherapy used. According to this notion, the nature of the preexisting MHC class I lesion in the cancer cell has a crucial impact on determining the final outcome of cancer immunotherapy. This SpringerBrief will present how MHC class 1 is expressed, explain its role in tumor progression, and its role in resistance to immunotherapy.  
UR  - http://dx.doi.org/10.1007/978-1-4614-6543-0
ER  -